Conclusion of non-exclusive discount agreements pursuant to §§ 130a para. 8/130c para. 1 SGB V for medicinal products with the active ingredient pegfilgrastim (L03AA13) within the framework of a so-called open-house model.
Abschluss nicht exklusiver Rabattverträge gemäß §§ 130a Abs. 8/130c Abs. 1 SGB V zu Arzneimitteln mit dem Wirkstoff Pegfilgrastim (L03AA13) im Rahmen eines sogenannten Open-House-Modells.
Germany · Eisenberg · how to bid here →
Your path to submission
- Deadline: 30 November at 23:59 — 55 days left.
- The submission point is stated in the notice (link on the right).
- Offer and evidence in: DEU.
- Collect your evidence — use the eligibility analysis above: it lists the requirements and, for known certificates, how to get them.
Clement What the numbers say about this buyer
- In this sector the buyer awards roughly every month (847 awards, most recently February 2026) — by that rhythm the next award was due around March 2026. The last award went to Novo Nordisk Pharma GmbH.n = 847
- 37% of the bids received came from other countries (27 procedures with a bid mix) — all bidders, not just the winners. Sector: 5%.n = 27
- 90% of the bids received came from small and medium-sized enterprises (27 procedures with a bid mix). Sector: 38%.n = 27
- The award came in at a median 56% of the estimated value (14 awards with both estimate and value) — pricing at the estimate is usually too high here. Sector: 87%.n = 14
- 68% of this buyer's awards went to companies that had already won here before (987 awards since 2018, spread over 320 companies). 32% went to new names.n = 987 awards since 2018
From this buyer's documented awards; comparison values from the same sector and country. Not a forecast, not legal advice. As of 04/10/2026.
Foreign bidders
In Germany · Medical equipment & pharma, 265 contracts went to foreign companies over the last 3 years (of 22,200 recorded awards) — mostly from Austria, Netherlands, France.
Submission language: DEU.
Typical field: median 1 (from 890 awards).
What the buyer is looking for
AOK Rheinland-Pfalz/Saarland - The health insurance company offers discount contracts with the active ingredient pegfilgrastim (L03AA13) to all interested pharmaceutical companies without a selection decision. Contracts are concluded within the framework of an ‘open house model’. The contracts offered are not exclusive; Contracts with all market participants (pharmaceutical companies) are desired by the AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse. In the Open House model, uniform conditions apply to all participants. Contractual content, conditions and access procedures are uniform – individual negotiations are not conducted. The contract duration is a maximum of 24 months, the earliest contract start date is 01.02.2025. All contracts end no later than 24 months after the date of the earliest start of the contract, regardless of the date of the respective conclusion of the…
Show full description
… contract. An accession or conclusion of a contract can take place within the 24-month period at the first of each month. There is a right of termination 6 weeks at the end of each month in accordance with the provisions of the contract. Further information on termination options can be found in the contract documents. The AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse reserves the right to replace the non-exclusive Open House discount contracts with exclusive discount contracts during the contract period within the framework of Europe-wide tender procedures. With the entry into force of advertised, exclusive discount contracts, the Open House contracts are terminated in accordance with the contractual regulation, i.e. the Open House contracts end automatically. Interested pharmaceutical companies can request the participation documents as well as the contract documents from the mentioned contact address. Contracts for the active substance pegfilgrastim (L03AA13) will be concluded for the first time with effect from 01.02.2025. Interested parties who would like to become contractual partners on this date must submit the contractual documents to the AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse by 31.12.2024. Access to the AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse is essential. Note: The first award in this procedure shall be made no earlier than 10 calendar days after the publication of this EU notice in the Official Journal. Later contracts can be concluded during the 24-month maximum term at the first of each month. In the case of interested parties who wish to become contractual partners on these subsequent dates, the receipt of the contract documents, including the annexes, must be submitted no later than the end of the month preceding the previous month of the desired start of the contract (e.g. receipt 30.04. at the start of the contract 01.06.). The exact deadlines for receipt will be announced with the contract documents. This publication does not constitute the award of a public contract within the meaning of the Public Procurement Coordination Directive 2014/24/EU of the European Parliament and of the Council or of public procurement law. Publication in the Supplement to the Official Journal of the European Union shall be carried out in order to ensure as much transparency as possible as regards the intended conclusion of contracts. In the absence of a publication form, the contract notice shall be used. The resulting conceptual requirements, such as the procedural designation ‘open procedure’, are solely due to the use of this notice form and the publication platform. A further meaning, in particular a submission to public procurement regulations, insofar as they are not obligatory for legal reasons, is not associated with this.
What you must prove — eligibility criteria
Im Rahmen dieses Vertrages dürfen grundsätzlich nur zugelassene und in Deutschland verkehrsfähige Arzneimittel abgegeben werden. Sofern ein Arzneimittel in der Lauer-Taxe als verkehrsfähig gelistet ist, gilt dieser Umstand als nachgewiesen. Falls ein Arzneimit… ▸▾
Contract
Who has won here before
| Company | Awards | Period |
|---|---|---|
| axicorp Pharma B.V. · EC Den Haag | 32 | 2017–2022 |
| Aliud Pharma GmbH · Laichingen | 28 | 2017–2023 |
| Abacus Medicine A/S · Kopenhagen | 27 | 2018–2023 |
| kohlpharma GmbH · Merzig | 26 | 2017–2023 |
| EurimPharm Arzneimittel GmbH · Saaldorf-Surheim | 25 | 2019–2023 |
How often this buyer tenders this
Who knows the rhythm prepares instead of reacting.